Recordati Industria Chimica E Farmaceutica S.P.A. (OTCMKTS:RCDTF – Get Free Report) saw a significant drop in short interest in July. As of July 15th, there was short interest totaling 129,033 shares, a drop of 32.8% from the June 30th total of 191,938 shares. Based on an average daily trading volume, of 32 shares, the short-interest ratio is currently 4,032.3 days. Approximately 0.1% of the company’s stock are sold short.
Recordati Industria Chimica E Farmaceutica Price Performance
Shares of OTCMKTS RCDTF opened at $58.00 on Friday. The business has a 50-day moving average of $58.71 and a two-hundred day moving average of $59.35. The company has a market capitalization of $11.97 billion, a price-to-earnings ratio of 20.69 and a beta of 0.25. Recordati Industria Chimica E Farmaceutica has a 1 year low of $55.88 and a 1 year high of $60.00. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.86.
Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported $0.91 EPS for the quarter. Recordati Industria Chimica E Farmaceutica had a return on equity of 34.46% and a net margin of 18.38%.The business had revenue of $810.70 million for the quarter.
About Recordati Industria Chimica E Farmaceutica
Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.
The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.
Featured Stories
- Five stocks we like better than Recordati Industria Chimica E Farmaceutica
- Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
Receive News & Ratings for Recordati Industria Chimica E Farmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati Industria Chimica E Farmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
